Zymtronix Unlocks New Frontiers in HMO Research with Expanded DSLNT Availability

Durham, NC – Zymtronix announced today a groundbreaking advancement in human milk oligosaccharide (HMO) research with a significant increase in the availability of Disialyllacto-N-tetraose (DSLNT). This innovation, driven by Zymtronix’s proprietary cell-free biocatalysis platform, eliminates a critical supply bottleneck, making DSLNT readily accessible to researchers worldwide.

DSLNT, a complex and vital HMO, has long been challenging to produce in sufficient quantities and purities for comprehensive research. Zymtronix’s proprietary “carbo core” platform, which eliminates the need for living cells, now enables efficient and sustainable production, opening new avenues for exploring DSLNT’s potential benefits.

“We’re thrilled to empower researchers with unprecedented access to DSLNT,” said Stephane Corgie, Chief Innovation Officer at Zymtronix. “By overcoming the limitations

of traditional production methods, we’re accelerating the pace of discovery and fostering a deeper understanding of this crucial molecule. This increased supply will fuel research across diverse fields, including infant nutrition, microbiome studies, and immunology. Zymtronix’s scalable technology ensures that future production can readily expand to meet growing research and industrial demands.”

Researchers and industrial partners interested in obtaining DSLNT or exploring collaboration opportunities are encouraged to contact info@zymtronix.com for a technical data sheet and further information.

About Zymtronix:

Zymtronix is a pre-commercial biotechnology company pioneering sustainable biomanufacturing with its proprietary, cell-free enzyme platform. By unlocking the full power of nature’s enzymatic systems, Zymtronix enables the efficient production of complex molecules for research and industrial applications—driving innovation across sectors from agriculture to nutrition, while reducing costs and expanding production possibilities.